1. The inter-relationships between receptor occupancy, inositol phospholipid metabolism and elevation of cytosolic free Ca2l in thromboxane A2-induced human platelet activation were investigated by using the stable thromboxane A2 mimetic, 9,11 -epoxymethanoprostaglandin H2, and the thromboxane A2 receptor antagonist, EP045. 2. 9,11-Epoxymethanoprostaglandin H2 stimulated platelet phosphatidyl- [3H]prostaglandin H2 binding) is similar to that for 9,1 1-epoxymethanoprostaglandin H2-induced [32P]phosphatidate formation and for elevation of cytosolic free Ca2+. 7. These observations indicate that human platelet thromboxane A2 receptor occupation is closely linked to inositol phospholipid metabolism and to elevation of cytosolic free Ca2l. Both such events may be necessary for thromboxane A2-induced human platelet activation.
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1. The inter-relationships between receptor occupancy, inositol phospholipid metabolism and elevation of cytosolic free Ca2l in thromboxane A2-induced human platelet activation were investigated by using the stable thromboxane A2 mimetic, 9,11 -epoxymethanoprostaglandin H2, and the thromboxane A2 receptor antagonist, EP045. 2. 9,11-Epoxymethanoprostaglandin H2 stimulated platelet phosphatidylinositol metabolism as indicated by the rapid accumulation of [32P] phosphatidate and later accumulation of [32P] phosphatidylinositol in platelets pre-labelled with [32p]p;.
These effects of 9,1 1-epoxymethanoprostaglandin H2 were concentration-dependent and half-maximal [32P] phosphatidate formation occurred at an agonist concentration of 54 + 8 nM. 3. With platelets labelled with the fluorescent Ca2+ indicator quin 2, resting cytosolic free Ca2l was 86+ 12nM. 9,1 1-Epoxymethanoprostaglandin H2 induced a rapid, concentration-dependent elevation of cytosolic free Ca2+ to a maximum of 300-700nm. Half-maximal stimulation was observed at an agonist concentration of 80 + 23 nM. 4. The thromboxane A2 receptor antagonist EP045 selectively inhibited 9,1 I-epoxymethanoprostaglandin H2-induced [32P]phosphatidate formation andelevation of cytosolic free Ca2 , indicating that both events are sequelae of receptor occupancy. 5. Human platelets contain a single class of stereospecific, saturable, high affinity (KD = 70+ 13nM) binding sites for 9,1 1-epoxymethano[3H]prostaglandin H2. 6. The concentration-response curve for receptor occupancy (9,1 1-epoxymethano-
[3H]prostaglandin H2 binding) is similar to that for 9,1 1-epoxymethanoprostaglandin H2-induced [32P]phosphatidate formation and for elevation of cytosolic free Ca2+. 7. These observations indicate that human platelet thromboxane A2 receptor occupation is closely linked to inositol phospholipid metabolism and to elevation of cytosolic free Ca2l. Both such events may be necessary for thromboxane A2-induced human platelet activation.
The arachidonic acid metabolites prostaglandin G,, prostaglandin H2 and thromboxane A2 are potent inducers of human platelet aggregation and secretion (Hamberg et al., 1974 (Hamberg et al., , 1975 . All three compounds appear to activate platelets by combining with the same plasma membrane located receptor, termed the thromboxane A2 receptor as Abbreviations used: 9,1 l-epoxymethanoPGH2, 9a,l lo-epoxymethanoprostaglandin H2; Ins, inositol; PtdIns, phosphatidylinositol.
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thromboxane A2 is the most potent endogenous agonist (MacIntyre, 1981; Armstrong et al., 1983) .
In view of the patho-physiological importance of arachidonate metabolites in haemostatis and occlusive vascular diseases (Smith, 1980 ) the mechanisms whereby those compounds induce platelet activation are of considerable interest. Mechanistic studies utilizing prostaglandin G2 or prostaglandin H2 are complicated by the rapid conversion, either enzymically or non-enzymically, of these compounds to an array of products, many of which possess biological activity (Christ-Hazelhof Vol. 219 et al., 1976; Moncada & Vane, 1979) . Similarly, mechanistic studies using thromboxane A2 are hindered by its instability (t = 30s at 37°C and pH 7.4) and rapid hydrolysis to the relatively inert metabolite thromboxane B2 (Hamberg et al., 1975) . These difficulties can be overcome by the use of stable compounds such as 9,1 1-epoxymethanoPGH2 (U44069), a stable prostaglandin endoperoxide analogue (Bundy, 1975) which binds to the platelet thromboxane A2 receptor and thus induces platelet activation by acting as a thromboxane A2-mimetic (MacIntyre, 1981 ; Armstrong et al., 1983) . In platelets, the major biochemical intermediaries that translate agonist-receptor combination into the final cellular response are believed to be cyclic AMP and cytosolic free Ca2 . An elevated intracellular cyclic AMP concentration is certainly associated with inhibition of platelet function (Salzman & Neri, 1969) and there is much controversy as to whether a reduction in the basal intracellular cyclic AMP concentration can lead to platelet activation (Haslam et al., 1978) . That platelet activation is associated with, and perhaps mediated by, an elevation of cytosolic free Ca2+ was indicated by studies using artificial means of increasing cytosolic free Ca2+ (Feinstein & Fraser, 1975; Knight & Scrutton, 1980) . This theory has been confirmed by direct estimation of cytosolic free Ca2+ using the membrane-permeant calcium indicator dye quin 2 (Rink et al., 1981) . Such an elevation of cytosolic free Ca2+ may arise by mobilization of Ca2+ from intracellular stores or by influx of extracellular Ca2 , presumably through some form of calcium channel (Gerrard et al., 1981; Owen & Le Breton, 1981) . Michell (1975) proposed that the biochemical basis underlying Ca2+ flux is agonist-induced turnover of membrane PtdIns. There is evidence that ADP, collagen and thrombin stimulate PtdIns turnover in platelets (Lloyd et al., 1972; Lloyd & Mustard, 1974; Rittenhouse, 1982) and the mechanisms of the thrombin effect have been analysed in detail, although rarely using human platelets (Lapetina, 1982) . Agonist-receptor combination can activate a Ptdlns-specific phospholipase C which hydrolyses PtdIns to diacylglycerol and Ins-1-P. Diacylglycerol may then be phosphorylated by diacylglycerol kinase to yield phosphatidate, which in turn can be reconverted to Ptdlns to complete the metabolic cycle, or can be acted upon by a phosphatidate-specific phospholipase A2 to yield lysophosphatidate and arachidonic acid (Billah et al., 1981) . Neufeld & Majerus (1983) Ca2+ from intracellular or extracellular sources (Tyson et al., 1976; Gerrard et al., 1979) . More recent evidence indicates that breakdown of polyphosphoinositides, PtdIns(4,5)P2 and Ptdlns(4)P, rather-than of PtdIns may be the initial event that follows receptor occupancy (Agranoff et al., 1983; Berridge, 1983; Drummond et al., 1984) . These polyphosphoinositides are known to bind Ca2+ avidly (Dawson & Hauser, 1970) and can be degraded by phospholipase C type enzymes to form diacylglycerol and Ins-1,4-P2 or Ins-1,4,5-P3 (Irvine, 1982) . Theoretically, receptor-mediated degradation of phosphoinositides by phospholipase C could participate in Ca2+ flux in several ways: (1) by directly liberating sufficient Ca2+ to mediate the cellular response; (2) by generating Ins-1,4,5-P3 which may act as a second messenger to mobilize internal Ca2+ (Streb et al., 1983) (Kawahara et al., 1980) . This enzyme governs the phosphorylation of specific proteins, although these appear to be implicated mainly in platelet degranulation (Kaibuchi et al., 1982) rather than in the initial stages of platelet activation.
In the present study, using a stable thromboxane A2-mimetic and a thromboxane A2 antagonist, we investigated the relationship between thromboxane A2 receptor occupation, stimulated inositol phospholipid metabolism and stimulated Ca2+ flux in order to gain some insight into the molecular mechanisms that link thromboxane receptor occupancy to platelet activation.
Experimental
Preparation of platelet-rich plasma Blood was obtained from the antecubital vein of healthy human volunteers, predominantly those who denied having taken drugs known to affect platelet function for at least 7 days. In some specific instances blood was obtained from donors who had taken aspirin (600mg by mouth) 2 days previously. Blood was collected into plastic tubes containing IO% (v/v) (lOOOg, 4min, (15) (16) (17) (18) (19) (20) . The supernatant platelet-rich plasma was aspirated into plastic tubes.
Radioligand binding studies
All procedures were carried out essentially as described by Armstrong et al. (1983) . Briefly, platelet-rich plasma was centrifuged (1600g, 10min, 1 5-20°C) in the presence of prostaglandin E1 (1.7 x 10-8M) and indomethacin (10-5M), and the resulting pellet was resuspended in a calcium-free, phosphate-free citrate buffer, pH 7.5, at 5 x 108 platelets/ml. Platelet suspension (1 ml) was then added to Eppendorf tubes containing various concentrations of 9,11-epoxymethano[3H]PGH2 in the presence or absence of excess unlabelled 9,1 1-epoxymethanoPGH2 and incubated at room temperature for 4min. Incubations were terminated by centrifugation (15OOOg, 2min) and rapid removal of the cell-free supernatant with a Pasteur pipette. Pellets were digested by incubation with hyamine hydroxide (1 M, 50°C, 5min) and neutralized by addition of HCI prior to transferring to scintillation vials. Phospholipid studies Those studies were carried out essentially as previously described (Maclntyre & Pollock, 1983) . Briefly, platelet-rich plasma was centrifuged (800g, 10min, 15-20°C) in the presence of prostaglandin I2 (3 x 10-7M) and the resultant pellet resuspended in calcium-free, phosphate-free, Hepes [4-(2-hydroxyethyl)-1 -piperazine-ethanesulphonic acid] buffer, pH 7.4, and incubated (37°C, 90min) with carrier-free [32P]orthophosphate (30pCi/ml). Platelets were then pelleted by centrifugation (800g, 10min, 15-20°C) in the presence of prostaglandin I2 (3 x 10-7 M). Pellets were resuspended in 1.5-fold the labelling volume of fresh buffer and aliquots (0.4ml, containing 0.5-1 mg of protein) were dispensed into plastic tubes at 37°C. Reactions were initiated by the addition of various concentrations of 9,1 1-epoxymethanoPGH2 (4p1) or vehicle (4jpl) in control samples. Antagonists or appropriate vehicle (<10pl) were incubated with platelets for 60 s before the addition of 9,1 1-epoxymethanoPGH2. Reactions were terminated by transferring the entire platelet sample into a glass test tube containing 2ml of chloroform/ methanol/lOM-HCl (25:50:4, by vol.) at room temperature (Lloyd et al., 1972) .
Lipids were extracted essentially by method B of Lloyd et al. (1972) , dried at 40°C under N2, separated by two-dimensional t.l.c. (Yavin & Zutra, 1977) and visualized by exposure to iodine vapour and/or autoradiography. Spots corresponding to Ptdlns and phosphatidate were scraped into vials and counted for radioactivity in a liquid-scintillation spectrometer.
Measurement ofplatelet cytosolic free Ca2+
Platelet cytosolic free Ca2+ was monitored by using the fluorescent quinoline dye, quin 2, which displays high affinity for Ca2+ and undergoes fluorescence changes resulting from Ca2+ binding . Platelet-rich plasma was incubated (37°C, 30min) with quin 2-acetoxymethylester which is membrane-permeant and crosses the plasma membrane, where it is rapidly hydrolysed by cytoplasmic esterases to the membrane-impermeant polycarboxylate anion that is quin 2. Quin 2 is thus trapped inside intact platelets and can report the resting concentration of cytosolic free Ca2+ and changes that result from exposure to agonists . Quin 2-labelled platelets were separated from plasma containing extraneous dye by gel-filtration on columns of Sepharose 2B equilibrated with a modified Hepesbuffered Tyrodes' solution (129mM-NaCl, 10.9 mM-trisodium citrate, 8.9 mM-NaHCO3, 0.56mM-glucose, 5 mM-Hepes, 2.8 mM-KCl, 0.8 mM-KH2PO4, 0.84mM-MgCl2, 2.4mM-CaCl2 and 0.35% bovine serum albumin, pH7.4). The quin 2 content of platelets was around 1 mmol/litre of cells. Gel-filtered platelets were stored at 37°C in stoppered plastic tubes, and, to compensate for the chelation of Ca2+ by citrate, the external free calcium concentration was adjusted to 1 mM by addition of CaCl2 immediately before use. Platelets (1 ml) were placed in 1 cm square quartz cuvettes at 37°C, and fluorescence was monitored in an Aminco-Bowman spectrophotofluorimeter at 37°C with standard monochromator settings of 339nm (excitation) and 500nm (emission).
Platelet function tests
Platelet aggregation was measured photometrically in 0.17 ml samples of platelets. Release of platelet dense granule constituents (ADP, 5-hydroxytryptamine) was monitored by using an isotope (5-hydroxy['4C]tryptamine) pre-labelling technique (Maclntyre et al., 1978) .
Other assays
Protein was estimated by the method of Lowry et al. (1951) .
Materials 15(S)-Hydroxy-9a,1 la-epoxymethanoprosta-5-cis,13-trans-dienoic acid (9a,11a-epoxymethano-PGH2), prostaglandin E1 and prostaglandin 12 were gifts from the Upjohn Co., Kalamazoo, MI, U.S.A. 9,1 I-Epoxymethano[3H]PGH2 (13.9 Ci/ mmol) and (± )-5-endo-(6'-carboxyhex-2'Z-enyl-6-exo- [N-(phenylcarbamoyl) hydrazonomethyl]-bicyclo[2,2, 1 ]heptane (EP 045) were prepared as described previously Armstrong et al., 1983 
Results
Before attempting to correlate agonist-induced biochemical events to cellular responses it is mandatory to ensure that platelet functional responsiveness is maintained under the conditions used to monitor the biochemical events. Accordingly, we monitored the effects of 9,11-epoxymethanoPGH2 on platelet aggregation using platelets prepared under conditions of [32P]Pi radiolabelling. Fig. 1 shows that 9,11-epoxymethano-PGH2 induces concentration-dependent platelet aggregation which is rapid and irreversible. Added fibrinogen (50,ug/ml) augments the aggregation responses but it is not a prerequisite for aggregation. Aggregation was not associated with significant release of the platelet dense granule marker,
5-hydroxy['4C]tryptamine (results not shown).
There is inter-subject variability in platelet responsiveness to 9,11-epoxymethanoPGH2. The threshold concentration at which it induces platelet aggregation is around 10nM, and maximum responses are observed at concentrations around 1 ,UM.
The optical techniques for monitoring platelet activation are acknowledged to be insensitive (Born & Hume, 1967) . However, given the rapidity of onset of platelet aggregation induced by 9,11-epoxymethanoPGH2 it is not unreasonable to assume that receptor-mediated transduction mechanisms should occur shortly after agonist addition. Fig. 2 and fibrinogen (50g/ml) was added. Platelet aggregation was monitored photometrically in 0. 17ml samples following the addition (at the arrows) of 9,11-epoxymethanoPGH2 at the concentrations indicated. Fig. 3 . The threshold concentration of agonist is around 10-20nM, and maximum stimulation of [32P]phosphatidate formation was observed at [9,l.l-epoxymethanoPGH2] = 330nM (n = 4) and at [9,1 1-epoxymethanoPGH2] = 1.1LM (n = 3). The calculated EC50 (the concentration of agonist that elicits 50% of the maximum response) is 54 + 8 nM (mean+ S.D., n = 7).
Using platelets labelled with quin 2, the estimated resting cytosolic free Ca2+ concentration was 86+ 12nM (mean+S.D., n = 6). 9,11-EpoxymethanoPGH2 produced a concentration-depend- ent increase in the cytosolic free calcium concentration (Fig. 4) . The changes in cytosolic free calcium induced by 9,1 1-epoxymethanoPGH2 occurred rapidly following addition of agonist and were essentially complete within lOs. The threshold concentration of 9,1 1-epoxymethanoPGH2 at which a Ca2+ flux was observed was around 10-30nM, and the maximum response was observed at (Armstrong et al., 1983) . Thus EP 045 can be termed a thromboxane A2 receptor antagonist. We therefore used EP 045 to confirm that 9,11 -epoxymethanoPGH2-induced [32P]phosphatidate formation and calcium flux were receptor-mediated events. [3H]PGH2 aitthe concentrations indicated, in the presence or absence of excess unlabelled 9,1 1-epoxymethanoPGH2 (11.4pM). Bound and free radioligand were separated by centrifugation (1 5000g, 2min). By subtracting the amount of radioligand bound in the presence of excess unlabelled 9,1 1-epoxymethanoPGH2 from that in its absence, specific (i.e. displaceable) binding was determined (0) (Armstrong et al., 1983 induced by 9,1 l-epoxymethanoPUH2 (330nM). At [EP 045] = 10,gm, the response to the agonist is abolished, and the I50 value for EP 045 (concentration of antagonist that reduces the agonist response by 50%) was 450+ 140nM (mean+S.D., n = 3). To confirm that the effect of EP 045 was selective for 9,1 1-epoxymethanoPGH2, we examined its effects on [32P]phosphatidate formation induced by other agonists, platelet-activating factor and vasopressin (Maclntyre & Pollock, 1982) . In these experiments, to eliminate any contribution from endogenous arachidonate metabolites, platelets were obtained from aspirin-treated donors. EP 045 (3 gM) abolished [32P]phosphatidate formation induced by 9,1 1-epoxymethanoPGH2 (l00nM) but had no effect on submaximal responses to vasopressin (100nM) and platelet-activating factor (100 nM).
When tested against 9,1 1-epoxymethanoPGH2-induced increase in platelet cytosolic Ca2+, EP 045 exerted a concentration-dependent inhibitory effect (Fig. 7) . This effect of EP 045 was selective for 9,1 1-epoxymethanoPGH2 in that responses of similar magnitude induced by platelet-activating factor were unaffected by EP 045 (<10 1uM) (results not shown). The involvement of intracellular Ca2+ concentration as a major determinant of platelet activawPGH2-intion derives from studies using calcium ionophores n platelets (Feinstein & Fraser, 1975) Platelets in medium of free [Ca2+10= 1 mM Fig. 7 . Effect of EP 045 on 9,11-epoxymethanoPGH2-induced changes in the fluorescence of quin 2-loaded platelets Plasma-free suspensions of quin 2-labelled platelets in a modified Hepes-buffered Tyrodes solution containing 1 mMexternal Ca2+ were prepared as described in the Experimental section. Platelets were incubated for 60s at 37°C with EP 045 at the concentration indicated or saline in control samples, and the fluorescence responses (excitation 339nm, emission 500nm) of I ml samples were monitored following the addition of lOOnM-9,1 1-epoxymethano-PGH2. The appropriate intracellular free Ca2+ calibration scale is shown at the right of the fluorescence records.
The data shown are typical of two similar experiments using platelets from different donors.
Vol. 219 cium-releasing activity of endogenous prostaglandin endoperoxides and thromboxane A2 may not be shared by exogenous arachidonate metabolites. Indeed, there is compelling evidence that exogenous prostaglandins G2, H2 and thromboxane A2 induce platelet activation by combining with distinct (thromboxane A2) receptors on the platelet plasma membrane (MacIntyre, 1981; Armstrong et al., 1983) . The nature of the coupling mechanisms that link thromboxane A2 receptor occupancy to platelet activation are not fully understood. In view of the rapid bio-conversion of prostaglandins G2 and H2 and the instability of thromboxane A2, such mechanistic studies can best be performed using stable prostaglandin analogues that act as thromboxane A2 mimetics in a variety of biological preparations (Coleman et al., 1981; Maclntyre, 1981) . Such studies indicate that platelet thromboxane A2 receptor occupancy is not linked to adenylate cyclase or guanylate cyclase nor to acyl hydrolase activation (Best et al., 1979; Di Minno et al., 1981) . As inositol phospholipid metabolism may be the receptor-mediated event that initiates Ca2+ flux in a number of systems, we examined the inter-relationships between thromboxane A2 receptor occupancy, inositol phospholipid metabolism, cytosolic free Ca2+ concentration and human platelet activation.
Phospholipid analyses were performed using platelets that had been incubated with [32p] (Siess et al., 1983 ) is comparable in magnitude to the change in cellular content of phosphatidate (Broekman et al., 1980) . A similar strategy has been used by Weiss et al. (1982) to monitor secretagogue-induced phosphatidate synthesis in parotid acinar cells. Although recent evidence implicates polyphosphoinositide metabolism rather than PtdIns metabolism as the initial event that follows occupancy of Ca2+-mobilizing receptors in several systems (Kirk, 1982; Berridge, 1983; Drummond et al., 1984) , it should be noted that whether PtdIns, Ptdlns(4)P or PtdIns(4,5)P2 is/are hydrolysed by a phospholipase C type enzyme, one of the initial products is 1,2-diacylglycerol which would be rapidly converted to phosphatidate by diacylglycerol kinase. Clearly, agonist-induced formation of [32P]phosphatidate could occur by mechanisms other than degradation of inositol phospholipids, for example (a) synthesis de novo from glycero-3-phosphate; (b) phosphorylation of diacylglycerol derived from other phospholipids; (c) phosphorylation of diacylglycerol derived from tri-' acylglycerol. We can preclude these alternative sources of agonist-induced phosphatidate formation as (a) synthesis de novo of phosphatidate, even in stimulated platelets, is relatively slow (Neufeld & Majerus, 1983) ; (b) human platelet phospholipase C shows an absolute specificity for inositol phospholipids (Rittenhouse-Simmons, 1979) ; (c) human platelets contain negligible triacylglycerol lipase activity (Lote & Lowery, 1979) .
The thromboxane A2 mimetic, 9,11-epoxymethanoPGH2, stimulates, in a concentrationdependent manner, human platelet activation, formation of [32P]phosphatidate and an elevation of the platelet cytosolic free Ca2+ concentration. As these events can occur in the absence of detectable platelet degranulation and in aspirin-treated platelets, they are independent of endogenous platelet agonists and must be mediated directly. (Fig. 3) and of elevation of intracellular Ca2+ (Fig. 4) . Thus, maximum phosphatidate formation and elevation of cytosolic Ca2+ are evoked when all the thromboxane A2 receptors are occupied by 9,11-epoxymethano-PGH2, indicating that there are few spare receptors (or little 'receptor reserve') in the system. In this respect, 9,1 l-epoxymethanoPGH,-induced platelet activation resembles peptidergic and aadrenergic stimulation of parotid acinar cells (Weiss & Putney, 1981) . It should be noted that this assessment of the receptor reserve for the natural agonist, thromboxane A2, may be an underestimate should 9,1 l-epoxymethanoPGH, act as a partial agonist on platelets as on thromboxane A2-sensitive smooth muscle preparations (Jones et al., 1984 . Because of the insensitivity of optical techniques for monitoring platelet activation, any comparison of the concentration-response relationship between platelet activation and the other parameters under investigation must be made with caution. Nevertheless, it is of interest that 9,11-epoxymethanoPGH2-induced platelet shape change and aggregation occurs over the same agonist concentration range as does increased Ca2+ availability and phosphatidate formation.
The observed stimulation of [32P]phosphatidate formation by 9,1 1-epoxymethanoPGH2 is apparently at variance with the findings of Rittenhouse & Allen (1982) . These workers, using unlabelled platelets or [3H]arachidonate-labelled platelets, reported that neither prostaglandin H2 nor a stable analogue, 11,9-epoxymethanoPGH2, was by itself an efficient stimulus of Ptdlns metabolism. However, both thromboxane A2 mimetics enhanced collagen-induced Ptdlns metabolism. The reasons for this discrepancy are not obvious. It is probable that [32P]P, labelling yields a more sensitive index of phosphatidate formation than does [3H]arachidonate labelling (cf. MacIntyre & Pollock, 1983) , or phosphorus determinations. The present studies were performed upon platelets within 3-4h of venepuncture, whereas Rittenhouse & Allen (1982) used platelets obtained within 15 h of venepuncture. As platelet responsiveness to thromboxane A2 mimetics declines with time interval after venepuncture (Di Minno et al., 1981) , the most likely explanation of the discrepancy is that in the latter situation the platelets utilized were unresponsive (or desensitized) to thromboxane A2 mimetics, unless primed by exposure to a different agonist, namely collagen.
Our findings indicate that human platelet thromboxane A2 receptor occupancy is closely linked to inositol phospholipid metabolism and to Ca2+ flux. However, the inter-relationships between inositol phospholipid metabolism, Ca2+ flux and platelet activation remain to be established. Rink et al. (1982) , using ionomycin, have reported that the threshold concentrations of cytosolic free Ca2+ necessary for platelet shape-change and aggregation are respectively 500 and 2000nM. In the present study, maximum platelet aggregation in response to 9,1 l-epoxymethanoPGH2 occurred when the cytosolic free Ca2+ concentration was below 700nM. Thus an elevation in the cytosolic free Ca2+ concentration per se cannot explain platelet activation induced by thromboxane A2 mimetics. Although agonist-induced breakdown of inositol phospholipids may be the link between receptor occupancy and Ca2+ flux (Michell, 1975; Berridge, 1981; Putney, 1981) both events may contribute to the platelet activation process. It is probable that Ca2+ and the immediate precursor of phosphatidate, diacylglycerol (via activation of protein kinase C) may act synergistically or even synarchically (Rasmussen, 1981; Kaibuchi et al., 1983; Michell, 1983) to mediate the cellular responses to thromboxane A2 receptor occupancy.
